Authors: Diane E Powell Richard A Cochrane Michael W J Davie
Publish Date: 2010/12/19
Volume: 88, Issue: 3, Pages: 223-230
Abstract
The aim of this study was to determine whether the boneresorption response to anastrozole differed according to initial patient age in postmenopausal women with breast cancer in a crosssectional study Secondmorning void urines were collected for measurement of urinary crosslinked Ntelopeptide of type I collagen uNTx corrected for creatinine and logtransformed from postmenopausal women 99 with breast cancer on anastrozole ABC 88 with newly diagnosed breast cancer NDBC and 137 communitydwelling healthy control HC women Bone mineral density BMD was also measured at the lumbar spine LS L2–L4 and the femoral neck FN in the ABC group uNTx nanomole bone collagen equivalents/millimole creatinine levels increased with age in HC subjects In patients 70 years anastrozole treatment led to a significant increase in uNTx compared with agerelated HC subjects 174 vs 155 P 0005 Patients 70 years showed no such increase compared to HC 172 vs 169 nonsignificant however NDBC women 70 years had uNTx levels significantly lower than HC women 159 vs 169 P 005 There was no difference in uNTx levels above and below the age of 70 years in NDBC women 156 vs 159 nonsignificant ABC women were more likely to have a positive LS BMD z score than agematched controls Anastrozole treatment increases bone turnover more in younger postmenopausal women with breast cancer than in older women compared to healthy controls Higher LS BMD in ABC patients may help protect against fracture
Keywords: